Please login to the form below

Not currently logged in
Email:
Password:

Webinar: AMNOG – One Year On

IMS Consulting Group and Booz & Co will discuss the changes to Germany’s pharma pricing system in the latest PMLiVE webinar on Monday 23 April

Germany Rhine

Once the first country in Europe to get innovative products, thanks to its favourable pricing structure, Germany used to be a popular launch destination for the pharmaceutical industry.

In December AstraZeneca's antiplatelet drug Brilique (ticagrelor) become the first drug to be backed under the country's new pricing assessment laws, but the introduction of AMNOG and the G-BA test has left many in pharma wondering if they would not be better off avoiding the country altogether.

On Monday 23 April at 12:30pm (UK time) PMLiVE's latest webinar, AMNOG - One Year, will feature speakers from IMS Consulting Group and Booz & Co discussing these important pricing changes and what they mean for pharma. To registor for the free webinar use the box below or click this link.

 

The webinar can be viewed on this page on Monday and then shortly after it finishes it will be available here in an archived form.

• PMLiVE's country report series also has more on the German healthcare market

20th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics